Fuzhou Pharmaceutical was established in March 2003 and is located in the scenic and talent-rich Fuzhou National High-Tech Industrial Development Zone, Jiangxi Province. Covering an area of 138 mu (approximately 92,000 square meters), it is a high-tech enterprise in Jiangxi Province. The company has established a provincial-level enterprise technology center, the Jiangxi Provincial Engineering Technology Research Center for Anti-allergic Drugs, and a postdoctoral innovation practice base. It is mainly engaged in the R&D and production of chemical APIs (Active Pharmaceutical Ingredients) and preparations.

The company's key API (Active Pharmaceutical Ingredient) — cetirizine hydrochloride, an exclusive variety — is specially supplied for the production of its own preparation, Cetirizine Hydrochloride Tablets. The core technology of this product has obtained three national invention patents. Another key API, tropisetron citrate, is exclusively supplied to Dongfu Pharmaceutical for the production of Tropisetron Citrate Injection (an exclusive variety of Dongfu Pharmaceutical). The tropisetron citrate API has obtained a total of four invention patents. The newly approved APIs, including isosorbide dinitrate, calcium gluconate, and nicardipine hydrochloride, are all supporting materials for the preparations of Dongya Pharmaceutical.

Except for cetirizine hydrochloride (which is used in tablet production), all other APIs produced by the company meet the injection-grade standards. The company's current API production capacity is as follows: 2.4 tons/year for cetirizine hydrochloride, 50 kg/year for tropisetron citrate (capable of producing 10 million ampoules of Tropisetron Citrate Injection), 300 kg/year for isosorbide dinitrate, and 1,000 kg/year for calcium gluconate. In addition, the company can produce pharmaceutical intermediates such as p-chlorodiphenylethanol (Grignard alcohol), azepane hydrochloride (intermediate amine salt), tropine alcohol, and indole-3-carboxylic acid.

The company's key product, Cetirizine Hydrochloride Tablets (an anti-allergic drug), is a national Class II new drug and an exclusive product worldwide. It is also a high-tech product of Jiangxi Province, an excellent new product of Jiangxi Province, and a major project product of Jiangxi Province. It has been awarded the title of "High-Quality Products from Jiangxi" (2nd Session) by the Jiangxi Provincial Department of Industry and Information Technology and the Jiangxi Provincial Administration for Market Regulation.

Fuzhou Pharmaceutical focuses on the R&D and production of anti-allergic drugs and APIs. It absorbs new technologies, innovates processes, refines product quality, and strives to build a harmonious, healthy, high-performance, dynamic "specialized, refined, characteristic and innovative" high-tech enterprise